Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling

[1]  Kornelia Polyak,et al.  Breast cancer: origins and evolution. , 2007, The Journal of clinical investigation.

[2]  Gurkan Bebek,et al.  FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells , 2012, Oncogene.

[3]  Wing-Kin Sung,et al.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state , 2011, Molecular systems biology.

[4]  M. Kaess.  From Biology to treatment , 2018 .

[5]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[6]  M. Fernö,et al.  Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up , 2013, Breast Cancer Research and Treatment.

[7]  W. Jung,et al.  Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis , 2015, Journal of Translational Medicine.

[8]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[9]  D. Jäger,et al.  NY‐ESO‐1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T‐cell and CD79a+ plasmacytic/B‐cell infiltration , 2007, International journal of cancer.

[10]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[12]  C. Betsholtz,et al.  Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. , 2009, Cancer research.

[13]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[14]  Timothy Marsh,et al.  Fibroblasts as architects of cancer pathogenesis. , 2013, Biochimica et biophysica acta.

[15]  Mårten Fernö,et al.  Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies , 2003, Acta oncologica.

[16]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[17]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Gascard,et al.  Carcinoma-associated fibroblasts: orchestrating the composition of malignancy , 2016, Genes & development.

[19]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[20]  Karl J. Dykema,et al.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[22]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[23]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[24]  K. Pietras,et al.  Functional subsets of mesenchymal cell types in the tumor microenvironment. , 2014, Seminars in cancer biology.

[25]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[26]  C. Betsholtz,et al.  A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. , 2004, Nature genetics.

[27]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[28]  Tao Liu,et al.  Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse , 2016, Nucleic Acids Res..

[29]  M. Fernö,et al.  Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study , 2012, BMC Cancer.

[30]  D. Hanahan,et al.  Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.

[31]  R. Cardiff,et al.  Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.

[32]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[33]  C. Betsholtz,et al.  A specific requirement for PDGF-C in palate formation and PDGFR-α signaling , 2004, Nature Genetics.

[34]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  C. Heldin,et al.  PDGF-C is a new protease-activated ligand for the PDGF α-receptor , 2000, Nature Cell Biology.

[36]  Wassim Raffoul,et al.  A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response. , 2016, Cancer cell.

[37]  T. Miyawaki,et al.  PDGFRα plays a crucial role in connective tissue remodeling , 2015, Scientific Reports.

[38]  A. Ashworth,et al.  BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. , 2010, Cell stem cell.

[39]  L. Trusolino,et al.  Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer , 2013, Oncogene.

[40]  Robert A. Weinberg,et al.  Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts , 2010, Proceedings of the National Academy of Sciences.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Fernö,et al.  The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer , 2014, PloS one.

[43]  M. Smalley,et al.  The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling , 2011, Journal of Mammary Gland Biology and Neoplasia.

[44]  Jinwon Seo,et al.  MET is a potential target for use in combination therapy with EGFR inhibition in triple‐negative/basal‐like breast cancer , 2014, International journal of cancer.

[45]  J. Reis-Filho,et al.  Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis , 2007, Journal of Clinical Pathology.

[46]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[47]  Elgene Lim,et al.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.

[48]  R. Baxter,et al.  Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer , 2015, BioMed research international.

[49]  Eleni G. Christodoulou,et al.  Assessing Computational Methods for Transcription Factor Target Gene Identification Based on ChIP-seq Data , 2013, PLoS Comput. Biol..

[50]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Ulf Eriksson,et al.  Angiogenesis stimulated by PDGF‐CC, a novel member in the PDGF family, involves activation of PDGFR‐aa and ‐ap receptors , 2002 .

[52]  Lior Pachter,et al.  Differential analysis of RNA-seq incorporating quantification uncertainty , 2016, Nature Methods.

[53]  Austin E. Gillen,et al.  Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen , 2016, Clinical Cancer Research.

[54]  S. Merajver,et al.  BRCA1 regulates human mammary stem/progenitor cell fate , 2008, Proceedings of the National Academy of Sciences.

[55]  Carlos Caldas,et al.  JARID1B is a luminal lineage-driving oncogene in breast cancer. , 2014, Cancer cell.

[56]  A. Giuliano,et al.  FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. , 2010, Cancer research.

[57]  Henry W. Long,et al.  Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. , 2015, Cell reports.

[58]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[59]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[60]  I. Ellis,et al.  C‐Met in invasive breast cancer , 2014, Cancer.

[61]  M. Augsten.  Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment , 2014, Front. Oncol..

[62]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[63]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Guojun Wu,et al.  PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. , 2015, Cancer research.

[65]  R. Dymock.  Origins and Evolution , 2010 .

[66]  Guy S. Salvesen,et al.  SnapShot: Caspases , 2011, Cell.

[67]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[68]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[69]  C. Sotiriou,et al.  Luminal breast cancer: from biology to treatment , 2013, Nature Reviews Clinical Oncology.

[70]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[71]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.